the impact of bcr-abl mutations on signaling pathway activation in cml
Published 1 year ago • 782 plays • Length 1:07Download video MP4
Download video MP3
Similar videos
-
4:02
testing for bcr::abl kinase mutations in cml and how they impact tki resistance
-
2:51
the genetic complexity of cml beyond bcr-abl1 & the clinical impact of additional abnormalities
-
1:08
ngs for kd mutational analysis in cml patients on tkis
-
1:57
impact of age on treatment outcomes in b-cell all
-
1:12
abl001 – a new bcr-abl inhibitor for chronic myeloid leukemia (cml) treatment
-
1:26
braf-mutated aml is associated with poor prognosis and myelodysplasia-related mutations
-
1:40
mutations in all and their implications for treatment decisions
-
18:21
non-bcr-abl1 molecular biomarkers of prognosis in cml
-
48:45
acute lymphoblastic leukemia (all)
-
4:25
imbrave150 in unresectable hcc
-
57:20
impactful biomarkers on clinical decision of ascvd
-
3:07
the impact of blast enumeration & co-occurring myelodysplasia-related mutations in npm1-mutated aml
-
2:47
clinical and prognostic implications of wt1 mutations in de novo and r/r aml
-
2:10
the impact of sf3b1 mutation in myelofibrosis
-
1:50
bcr-abl1 tkd mutation testing using ddpcr in a clinical hematology laboratory q&a: part 1
-
2:09
predictors of achieving undetectable bcr::abl1 in patients with all
-
1:49
trailr2/cdh17 antibody (bi 905711): mechanism of action
-
2:01
impact of comorbidities on patient selection for combination therapies in cll
-
1:41
bcr-abl1 tkd mutation testing using ddpcr in a clinical hematology laboratory q&a: part 2
-
1:22
role of brca mutations in bc
-
4:14
imbrave150 trial: frontline treatment of advanced hcc
-
1:24
triple-negative myelofibrosis: disease features and outcomes